-- First inhaled mRNA therapeutic delivered in multiple doses to the lungs of CF patients is generally safe and well tolerated; no observed pattern of increases in ppFEV1 --
-- Data supports advancing mRNA therapeutics for pulmonary diseases; additional translational research ongoing to optimize future clinical development of mRNA cystic fibrosis programs, including MRT5005 and a next-generation CF candidate --
-- Company committed to advancing innovative mRNA therapeutics for all patients with CF; Phase 1/2 clinical trial for MRT5005 ongoing and next-generation CF candidate anticipated to enter IND-enabling studies in 2H 2021 --
-- Conference call today at 4:30 pm ET --
Translate Bio will host a conference call and webcast today at 4:30 PM ET to discuss the second interim results from the single-ascending and multiple ascending dose portions of its Phase 1/2 clinical trial of MRT5005 in patients with CF. The live webcast can be accessed on the investor page of Translate Bio’s website at https://investors.translate.bio/investors/news-and-events. The conference call can be accessed by dialing (877) 377-8524 (toll-free domestic) or (629) 228-0742 (international) and using the conference ID 3383727. A replay of the webcast will be available on Translate Bio’s website approximately two hours after the completion of the event and will be archived for up to 30 days.
https://finance.yahoo.com/news/translate-bio-announces-results-second-200500790.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.